TNFRSF8 and post-transplant lymphoproliferative disease: Recently, novel insights into pathogenesis (33) and treatment strategies for PTLD have emerged, including adoptive immunotherapy and targeted therapeutics, such as tabelecleucel, CAR-T cells, and CD30-based therapy (34), that could substantially improve outcomes.